New US study data suggests exercise could increase lifespan after treatment for breast cancer

A new study conducted by researchers from the University of Southern California in Los Angeles, explains how aerobic and resistance exercise can increase life expectancy for patients who have successfully completed breast cancer treatment. According to National Cancer Institute estimates, in 2017 there were approximately 252,710 new diagnoses of breast cancer in the United States.

Continue Reading

NICE recommend Eisai’s lenvatinib for treatment of advanced renal cell carcinoma

Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib

Continue Reading

Three new treatments approved for use on NHS Scotland, including hepatitis C

Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C. Eli Lilly’s Lartruvo was approved for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues within

Continue Reading

Novartis & Bristol-Myers Squibb to collaborate on cancer treatments

Novartis has entered a clinical research collaboration with Bristol-Myers Squibb to investigate the safety, tolerability, and efficacy of Mekinist in combination with Opdivo and Opdivo + Yervoy regimen. The cancer treatments are being used as a potential option for metastatic colorectal cancer in patients with microsatellite stable tumours where the tumours are proficient in mismatch

Continue Reading

MHRA accept Roche’s bladder cancer immunotherapy drug for Early Access to Medicines Scheme

Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from

Continue Reading

Cancer Research UK reports immunotherapy drug that can extend life of cancer patients

A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with

Continue Reading

NHS England unveils investment in cancer services

Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines.   Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accelerator) machines, as part of a £130-million investment in radiotherapy

Continue Reading